Comments by "红火树 RedFireTree" (@firetree2007) on "NationalDefence" channel.

  1. 8
  2. 6
  3. 3
  4. Rupam Sarkar  yes, read the history first, those are your excuses?? so tell me, why Hinduism cannot unite the whole India if majority of people live in the India proper believe in it? if Buddhism is so good, why majority of Indians would not accept it?? but more intelligent people welcomed it?? Indians can never realize or will never want to realize, the problem is their Hinduism Hinduism covers everything, explains everything, but cannot solve anything in real life, only give them temporary spiritual relief, Hinduism is spiritual opium for India. with Hinduism: 1. Indian people cannot resist numerus and continued invasions from all kinds of intruders through out the history for thousands of years. this made India has no history, or history that we know of. what India has was just waves after waves of foreign rulers rule on this non-resistance and non-change land. 2. India has no progress in science and technology compare to what achieved to their ancestors, they lag behind in the world in education and in science 3. this let India also slow in economical development, in 1947, India had the similar GDP with China, now India's GDP is only 1/5 of China's 4. Hinduism cannot help India to make world class advanced weapons. 5. Hinduism did not help India to lift 330 million people from poverty line, and made India to have world largest slums. 6. Hinduism did not help India to win any war as shown in 1962 to China, in it India army armed with Hinduism suffered 4000 causalities and 4000 surrendered to PLA in summary: Seeking truth from facts, not from Hinduism should be the way for India and for all the people.
    3
  5. 2
  6. 2
  7. 2
  8. 2
  9. 2
  10. 1
  11. 1
  12. 1
  13. 1
  14. 1
  15. 1
  16. 1
  17. 1
  18. 1
  19. 1
  20. गुमनाम व्यक्ति India's Solution To Drug Costs: Ignore Patents And Control Prices - Except For Home Grown Drugs John LaMattina John LaMattina Contributor i Pharma & Healthcare I cover news on drugs and R&D in the pharma industry Drug pricing is a major issue in India. The Indian government believes that the prices of lifesaving drugs shouldn’t be set by market forces. In a country where very few people have health insurance, 70% of Indians pay for healthcare expenses out of their own pockets. When it comes to cancer drugs, the problem is even more acute. There is no way that people in India can pay even a fraction of the cost for drugs that can be priced at $50,000/year in the West. This issue was again in the news last week when the Indian Supreme Court denied a patent application for Glivec (also known as Gleevec), an important treatment for leukemia made by Novartis. (Derek Lowe has done a great job in explaining the nuances of this patent decision, which won’t be repeated here.) Given that there is no patent for Glivec in India, any generic drug manufacturer in India can now make and sell this drug, which will be priced at a fraction of what Novartis charges in the rest of the world. This is good for the company that will profit from usurping all of the R&D that Novartis put into the discovery and development of Glivec. It is also good for patients who couldn’t afford Glivec. However, it must be noted that Novartis provides Glivec free of charge to 16,000 patients in India, roughly 95% of those who need it via the Novartis “Glivec International Patient Assistance Program”. The remaining 5% are either reimbursed, insured, or participate in a very generous co-pay program. Thus, not granting a patent for Glivec really hasn’t prevented patients from getting this life-saving medication. The Glivec situation is not unique. India has granted compulsory licenses to other cancer drugs, including Bayer’s Nexavar, Roche’s Tarceva, and Pfizer’s Sutent. These licenses allow India generic drug manufacturers to make these drugs with impunity. These actions have been justified by the secretary of India’s Pharmaceuticals department in the following way: “We need to ensure that expensive drugs are available at affordable rates to the poor.” It is hard to argue with that philosophy. However, India is expanding this policy beyond expensive cancer drugs. Again, just this past week, the Indian Supreme Court refused to prevent an Indian generic manufacturer, Glenmark Pharmaceuticals, from manufacturing and selling Merck’s diabetes drug, Januvia, in India. Merck will likely appeal this decision. While it is an important drug, Januvia does not carry an expensive price tag. In fact, when it was launched in India, Merck charged $0.86/tablet, one-fifth the US cost. Nevertheless, despite recognizing the need to make Januvia affordable in India, Merck’s intellectual property for this drug will be ignored in this country for the foreseeable future. In addition to not granting patents for new drugs, the Indian government sets prices for drugs that are patented, but this is not just for expensive medications. There are now 348 drugs that have price caps. However, India has now introduced a new element to this policy. Drugs that have some form of innovation that can be attributed to Indian researchers can be IMMUNE from price controls for five years. Three types of innovation can qualify for this benefit: 1) drugs that arise from indigenous R&D; 2) improvements by an Indian company on a process for making an existing drug; 3) development of a new drug delivery system by Indian R&D. The rationale for this policy was explained by a government official: “This would spur innovation and make sure price-control regime doesn’t dissuade pharma firms from research and development”. You can also envision that these new rules could be used by Indian generic companies to circumvent pharmaceutical company patents . For example, what is to stop an Indian company from developing a new process for making an important new drug developed by a non-Indian pharma company? It would not be surprising for the Indian government to allow a patent on this process and again the innovative company would be out of luck in protecting their commercial rights for this medicine in India.
    1
  21. I really worried about India, something fundamentally wrong. When you make this kind plan, you are planing to acquire the weapons to match against for the future enemy's threat, not for now. however, all the planed weapons are not even match up to what your enemy has today. none of them are the most advanced weapon today, none of them has any stealthy capability and none of them are 5 th. gen. fighters. Game changer?? just a joke, none of them is. Indian's like to just say that they think is good, however, you need to compare in technical details, not just based on what you believe or think for jet fighters, you need to compare 1. engine (J20 uses WS-15, with max power about 197 kn, to check Rafale engine, less than 100 kn) 2. radar (J20's radar with about 1970-2200 T/R, Rafale, 850. ) 3. RCS (J20, 0.001 and less, Rafale? 0.5) 4. range (for this we only compare internal fuel capacity, J20, 25 tons, Rafale? 4.8 tons) 5. weapon (J20 can use PL12, with 120 km range, and PL 15 with over 300 km range, Rafale?? meteor? 120 km) tell me, why Rafale is so good, 36 of them are facing over 1000 3rd gen. and above Chinese fighters, how can them be a game changer or change anything?? 36 Rafale with $240 M each will cost India people $8640 million or $8.6 billion, OK, then China need to match up this threat from India, let's say make more J20 which cost $110 M each, with the same amount of money, China will make 72 J20s, wait, since China's military budget is 3 times of India's therefore, with the same ratio and no more burden for China, China will make over 216 J20s for India's 36 Rafale, without extra efforts for China. in conclusion: India is spending so much time and money and efforts for things will not work and useless in future.
    1
  22. 1
  23. 1
  24. 1
  25. 1
  26. 1
  27. 1
  28. 1
  29. 1
  30. 1
  31. 1
  32. 1
  33. 1
  34. 1
  35. 1
  36. 1
  37. 1
  38. 1
  39. 1
  40. 1
  41. 1
  42. 1
  43. 1
  44. 1
  45. 1
  46. 1
  47. 1
  48. 1
  49. 1
  50. 1
  51. 1
  52. 1
  53. 1
  54. 1
  55. 1
  56. 1
  57. 1
  58. 1
  59. 1
  60. 1
  61. 1
  62. 1